** Shares of medical device maker Zimmer Biomet ZBH.N up 1.3% at 108.25 premarket
** Brokerage J.P.Morgan upgrades stock to "overweight" from "neutral"; raises PT to $128 from $125
** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters
** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market
** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance
** 11 of 31 brokerages rate the stock "buy" or higher, 18 "hold" and two "sell"; with a median PT of $122.50
** Up to Monday's close, stock has fallen ~12% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.